Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech vs. Shorts -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (313)	1/13/2000 6:01:00 PM
From: Biomaven	Read Replies (1) \| Respond to of 427

The AC committee today gave SNRS a favorable verdict. I was too chicken to play this one long, although I was sorely tempted. Around 8 1/2 million shares short in December, so this is another substantial loss for the shorts. Avalon called this one correctly initially, but I don't know if they subsequently changed their adverse position. Peter

To: Biomaven who wrote (313)	1/15/2000 12:57:00 AM
From: Neuroguy	Read Replies (1) \| Respond to of 427

Peter - the short list you gave as a percentage of market cap - isn't the percentage of the float a bit more of a guide? For example, in the case of CLPA, the percentage of the float is about 32%!! biz.yahoo.com That's a LOT of stock to have to cover on the open market, especially in a limited period of time. Plus the longs have been actively moving their shares into cash to prevent it from being borrowed (limiting further shorting). There was a collective effort generated by longs on the Raging Bull CLPA board to this, and they represent just over 5M shares of a 16.2M float. That's a very interesting list nonetheless. Some of those stocks have made tremendous gains of late.

To: Biomaven who wrote (313)	1/15/2000 1:09:00 AM
From: Miljenko Zuanic	Read Replies (1) \| Respond to of 427

Peter, From list of 20 larger shorts (thanks for list), I can understand weak rationale for some of the stocks, but none for ALKS. The near future of the company depend on ProRelease-EPO formulation and MediSorb-Risperidone. Because ProLease seams to work fine and they (J&J) are well into PIII trial (and ready to start MediSorb PIII), the IRATIONALE must be that this technologies is crapshot. I can't believe that this all ALKS short are hedge position??? Miljenko